Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Restructuring Costs (2023 - 2025)

Sunshine Biopharma (SBFM) has disclosed Restructuring Costs for 5 consecutive years, with $614661.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Restructuring Costs rose 6.06% year-over-year to $614661.0, compared with a TTM value of $3.3 million through Sep 2025, up 18.38%, and an annual FY2024 reading of $3.1 million, up 45.17% over the prior year.
  • Restructuring Costs was $614661.0 for Q3 2025 at Sunshine Biopharma, down from $806605.0 in the prior quarter.
  • Across five years, Restructuring Costs topped out at $925878.0 in Q1 2025 and bottomed at $544215.0 in Q3 2023.
  • Average Restructuring Costs over 3 years is $750173.1, with a median of $759925.0 recorded in 2024.
  • Peak annual rise in Restructuring Costs hit 13.09% in 2025, while the deepest fall reached 1.61% in 2025.
  • Year by year, Restructuring Costs stood at $544215.0 in 2023, then surged by 66.49% to $906056.0 in 2024, then tumbled by 32.16% to $614661.0 in 2025.
  • Business Quant data shows Restructuring Costs for SBFM at $614661.0 in Q3 2025, $806605.0 in Q2 2025, and $925878.0 in Q1 2025.